329 results about "Elevated creatinine" patented technology

The invention discloses a xanthine oxidase inhibitory peptide with a kidney improving function and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is screened out by conducting enzymolysis, separation and purification on litopenaeus vannamei processing by-products and utilizing a molecular docking technology, the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Leu-Gly-Pro-Pro-Pro. And the half inhibition concentration of the polypeptide is 2.356 + / -0.2448 mM. The xanthine oxidase inhibitory peptide is proved to have an improvement effect on hyperuricemia mice, the improvement effect is mainly characterized by reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and livers of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and Toxinpred prediction shows that the xanthine oxidase inhibitory peptide has the effect of inhibiting the activity of xanthine oxidase (XOD) in the serum and livers of the mice. The xanthine oxidase inhibitory peptide is free of toxic and side effects, so that the xanthine oxidase inhibitory peptide has a wide application prospect in preparation of food or drugs for improving renal functions.

The invention discloses a xanthine oxidase inhibitory peptide with uric acid reducing activity and application thereof, and belongs to the technical field of biological medicines.The xanthine oxidase inhibitory peptide is obtained by conducting enzymolysis, separation and purification on processing byproducts such as litopenaeus vannamei heads and shells with xanthine oxidase inhibitory activity. The xanthine oxidase inhibitory peptide is screened by using a molecular docking technology, and the amino acid sequence of the xanthine oxidase inhibitory peptide is Pro-Pro-Val-Pro-Pro-Pro. The xanthine oxidase inhibitory peptide has an XOD (X-Oxidase) half inhibitory concentration of 3.181 + / -0.1786 mM. The invention further proves that the xanthine oxidase inhibitory peptide has a certain improvement effect on hyperuricemia mice, and the xanthine oxidase inhibitory peptide mainly has the effects of reducing the content of serum uric acid, creatinine and urea nitrogen of the hyperuricemia mice, inhibiting the activity of xanthine oxidase (XOD) in serum and liver of the mice, inhibiting synthesis of uric acid and improving kidney injury of the mice, and the xanthine oxidase inhibitory peptide has a certain improvement effect on the hyperuricemia mice through Toxinpred prediction. The xanthine oxidase inhibitory peptide uric acid reducing peptide is free of toxic and side effects and has a wide market application prospect.

Methods of administering sotalol hydrochloride in an amount effective for treating one or more cardiovascular disease or disorder in pediatric patients are described and include IV and / or oral doses based on age-specific creatinine clearance ranges.

The invention belongs to the technical field of medicines, and particularly relates to application of eupatorium chinense extract in preparation of a medicine for treating gout. Researches show that the eupatorium chinense extract and the active components thereof have good biological activity and can inhibit the activity of xanthine oxidase (XOD). Molecular docking experiments also show that the eupatorium chinense extract and xanthine oxidase have good binding energy. Further research finds that the eupatorium chinense extract can reduce the levels of uric acid and creatinine in serum in a hyperuricemia mouse body, and has good uric acid reducing activity. In the field of treatment of hyperuricemia and gout, many traditional medicines have many adverse reactions. Compared with the prior art, the eupatorium chinense serving as a traditional Chinese medicine provides a safe and effective natural medicine for treating hyperuricemia and gout or gout complications due to the efficient uric acid reducing effect of the eupatorium chinense.

The invention discloses an intestinal strain capable of effectively regulating uric acid metabolism, a microbial agent of the intestinal strain and application of the intestinal strain in uric acid reducing products, and belongs to the technical field of microorganisms. According to the enterococcus pluvialis ZQ205, the enterococcus pluvialis ZQ205 which is free of toxic and side effects and capable of effectively relieving and treating the hyperuricemia is found for the first time, and the collection number of the enterococcus pluvialis ZQ205 in the China Center for Type Culture Collection is CCTCC NO: M 2025844; the strain can significantly reduce the levels of uric acid, creatinine and urea nitrogen in serum of mice, can effectively reduce the levels of inflammatory factors such as IL-6 and TNF-alpha in serum of hyperuricemia mice, and can improve kidney injury caused by hyperuricemia.

The invention discloses a fungus extract capable of effectively regulating uric acid metabolism and relieving inflammation as well as a preparation method and application of the fungus extract, and belongs to the technical field of deep processing of edible fungi. Schizophyllumcommuneh and poplar phellinus sporocarp are mixed and extracted, and the prepared fungus extract can effectively inhibit activity of xanthine oxidase in serum and liver of mice, reduce content of uric acid, creatinine, urea nitrogen and the like in serum and promote excretion of uric acid, creatinine, urea nitrogen and the like in urine; meanwhile, the content of inflammatory markers such as IL-6 and TNF-alpha in mouse serum can be effectively reduced, inflammatory infiltration of liver and kidney cells is relieved, and the problem that an existing edible mushroom extract is not ideal in treatment effect on hyperuricemia is solved.

The invention relates to the technical field of medical data analysis, in particular to a kidney injury prediction system based on big data, which comprises a physiological data processing module, a fluctuation analysis construction module, a dynamic weight evaluation module, a cross-domain data scheduling module and a risk trend prediction module. According to the method, through timestamp standardization and continuous recombination of the acute kidney injury physiological data, the consistency of multi-source monitoring data in the time dimension is ensured, drifting and dislocation are eliminated, the time sequence integrity is improved, fluctuation points of serum creatinine and urine volume are extracted, sensitive time slices are recognized, and high-risk time point early warning is achieved; a rate change comparison mechanism is introduced, a physiological factor weight sequence is generated, factor influence evaluation is enhanced, uploading frequency and a time delay state are combined, high-reliability nodes are screened, data continuity and real-time performance are improved, index trend deviation is tracked, a mode label is generated, and timeliness and accuracy of renal function change prediction are improved.

The invention belongs to the field of biological medicines, and particularly discloses application of a Ptprj agonist GJ103 in preparation of a medicine for treating acute kidney injury (AKI) induced by cisplatin. In-vivo and in-vitro experiments prove that the GJ103, by activating Ptprj, can significantly down-regulate expression of pro-apoptotic protein Bax and Cleved Caspase-3, up-regulate anti-apoptotic protein Bcl2 and reduce infiltration of inflammatory factors TNF-alpha and IL-6, so that apoptosis and inflammatory response of renal tubular epithelial cells are relieved. In in-vivo experiments, GJ103 (20-40mg / kg / day) can reduce serum creatinine and urea nitrogen levels of cis-platinum model mice and improve pathological injuries such as renal tubule dilatation; in in-vitro experiments, 20-40 [mu] M of GJ103 can inhibit apoptosis of renal tubular epithelial cells and reduce expression of renal injury markers NGAL and Kim-1. The pharmaceutical composition contains GJ103 and a pharmaceutical carrier, the preparation form can be a 4mg / mL injection (the purity is greater than or equal to 99.46%) or an oral preparation, and a new strategy is provided for clinical treatment of cisplatin renal toxicity.

The invention discloses application of oligopeptide in preparation of a medicine for treating and / or preventing diabetic nephropathy. The oligopeptides comprise oligopeptides with the amino acid sequence of SEQ ID NO: 1: LNLYP and derivative sequences or conservative substitution variants of the oligopeptides. The oligopeptide can significantly improve renal function indexes of mice with diabetic nephropathy, such as UACR, serum creatinine, urea nitrogen and the like, enhance podocyte barrier integrity and inhibit accumulation of advanced glycosylation end products AGEs in kidney tissues, and provides a basis for development of novel drugs for treating diabetic nephropathy.

The invention belongs to the technical field of biological medicines, and particularly relates to a morinda officinalis-synanthrin composition and application thereof in renal fibrosis products. The radix morindae officinalis-synanthrin composition provided by the invention is prepared from radix morindae officinalis polysaccharide, synanthrin and water, the synergistic effect of the two polysaccharides can be exerted, the physical and chemical properties and biological activity of the radix morindae officinalis-synanthrin composition can be improved, the metabolic rate of the kidney to urea nitrogen creatinine can be remarkably increased, the fibrosis positive area can be remarkably reduced, and the bioavailability of the radix morindae officinalis-synanthrin composition is improved. The traditional Chinese medicine composition has a remarkable effect on treating renal fibrosis diseases. The raw materials of the composition are based on natural polysaccharides, so that the composition has good safety and degradability, and meets the high requirement of the medical field on the safety of biological materials. Compared with an existing single component, the compound design can achieve the multi-target effect, the treatment effect is remarkably improved, and the compound medicine has the large market competitive advantage.

The invention belongs to the technical field of biological medicines, and particularly relates to application of poecilobdella manillensis in preparation of a medicine for treating renal injury. The invention provides a new application of poecilobdella manillensis in preparation of a medicine for treating renal injury, serum biochemical index detection proves that the poecilobdella manillensis can effectively reduce serum creatinine and blood urea nitrogen levels, increase serum albumin and total protein content, remarkably improve glomerular filtration function and protein metabolism function, and improve renal function. And the improvement degree of the traditional Chinese medicine composition is superior to that of a traditional Chinese medicine contrast. Although the curative effect is slightly poorer than that of a chemical drug group, the safety advantage is remarkable. The poecilobdella manillensis can comprehensively regulate renal function metabolism indexes, relieve kidney injury and avoid common side effects of chemical drugs, provides a new choice for clinical treatment of kidney injury, and is especially suitable for chronic kidney disease patients needing long-term treatment.

The invention provides a clinical rehabilitation data management and evaluation system for a rhabdomyolysis patient, and relates to a medical information management system. The system comprises an index acquisition module, a rate detection module, a curvature analysis module, a node identification module and a trend construction module. According to the method, the rate difference sequence of creatine kinase and myohemoglobin and the curvature sequence of urine sodium and serum creatinine are compositely calculated, the limitation of traditional single-parameter static analysis is broken through, the dynamic capture of a multi-index collaborative trend is realized, and a joint evolution label system is constructed by combining the consistency judgment of creatine kinase and blood potassium concentration change directions; according to the method, multi-system interaction risk nodes are accurately positioned, statistics is performed on direction consistency proportional distribution of myoglobin and serum creatinine in an association time period, discrete parameter association is converted into a dynamic visual model, and the problems of data discreteness misjudgment and collaborative evolution mode splitting in the traditional technology are solved. And a multi-dimensional dynamic evaluation framework of the rhabdomyolysis rehabilitation process is provided for clinic.

The invention discloses a construction method of a rivaroxaban population pharmacokinetic model and application of the rivaroxaban population pharmacokinetic model in an individualized medication prediction model, and relates to the field of biological information. According to the invention, a high performance liquid chromatography-tandem mass spectrometry method is adopted to determine the blood concentration of a rivaroxaban taking person, and a DNA sequencing method is adopted to determine the gene polymorphism of related metabolic enzymes CYP3A4 and CYP3A5 and transporters ABCB1 and ABCG2 of the rivaroxaban taking person; collecting data to establish a rivaroxaban group pharmacokinetic model, performing internal verification, and evaluating the stability and prediction performance of the model; in the final PPK model, the influence of the creatinine clearance rate, the ABCB1rs1045642 and the health condition on the clearance rate is the greatest; the experimental verification result shows that the model has good predictability and is accurate and reliable; the method can be applied to an individualized medication prediction model.

The invention provides novel application and a method of asiaticoside. The method comprises the following steps: S1, extraction: taking a centella asiatica medicinal material, performing coarse crushing, adding ethanol, performing reflux extraction, performing filtration, and combining filtrate for standby application; s2, concentrating: concentrating the ethanol extracting solution under reduced pressure until no alcohol smell exists, centrifuging, and reserving supernate for later use; s3, carrying out D101 column chromatography; s4, alumina column chromatography; s5, performing concentration; s6, drying; s7, dissolving with methanol, adding water, standing, and monitoring clear liquid and crystallization conditions in a liquid phase; s8, filtering after crystallization is finished, washing with ethanol, drying crystals under the conditions that the vacuum degree is-0.06 to-0.08 mpa and the temperature is 60-70 DEG C, and crushing and sieving dry paste to obtain asiaticoside; specifically, the new application comprises reduction of uric acid (UA), urea (UREA), creatinine (CREZ), low-density lipoprotein cholesterol (LDL-C), high-density lipoprotein cholesterol (HDL-C) and total cholesterol (CHOL) in serum of a hyperuricemia model SD rat, and reduction of damage of hyperuricemia to kidney. And the yield of asiaticoside extracted by the method is high and is about 84%.

The invention belongs to the technical field of nano-enzymes, and particularly relates to a preparation method and application of a porous RuO2 nano-enzyme for detecting creatinine. Comprising the following steps: ultrasonically dispersing Ca (NO3) 2.4 H2O, RuCl3 and glycine in deionized water to obtain a mixed solution A; dissolving sodium alginate in deionized water, and uniformly stirring to obtain a mixed solution B; injecting the mixed solution B into the mixed solution A, slowly stirring to form bimetallic hydrogel, washing with deionized water, and freeze-drying to obtain a solid A; calcining the solid A to obtain a solid B; and adding the solid B into hydrochloric acid for ultrasonic dispersion, stirring for a period of time, and centrifugally washing and drying the precipitate in vacuum to obtain the loose and porous RuO2 nano-particles. The nanoparticles prepared by the invention have abundant pore structures and great specific surface area, active sites can be fully exposed, and the POD enzyme activity is remarkably improved.

The invention belongs to the technical field of biological medicines, and particularly discloses a novel application of Epiblastatin A in preparation of a medicine for relieving cisplatin-induced acute kidney injury. The application disclosed by the invention for the first time reveals that by inhibiting the activity of Casein Kinase 1 (CK1) kinase, Epiblastine A can obviously relieve renal dysfunction and kidney tissue structure damage caused by cis-platinum. Experiments prove that the compound can effectively reduce serum creatinine and urea nitrogen levels, significantly improve renal tubule pathological injury, down-regulate expression of renal injury early-stage specific biomarkers KIM-1 and NGAL, and definitely inhibit renal tubule epithelial cell apoptosis in an in-vitro model. The invention also provides a specific pharmaceutical composition containing the Epiblastin A and a preparation form of the specific pharmaceutical composition. The invention provides a brand new mechanism and a high-efficiency and low-toxicity treatment strategy for clinically preventing and treating cisplatin dosage-limited renal toxicity, and has important clinical application value.

The present invention relates to a uric acid-lowering probiotic complex and its application. The probiotic complex comprises Lactobacillus reuteri FPH2951 and Bifidobacterium breve FPHC4024; wherein Lactobacillus reuteri FPH2951 is classified as Lactobacillus reuteri and has a deposit number of GDMCC No. 62946; and Bifidobacterium breve FPHC4024 is classified as Bifidobacterium breve and has a deposit number of GDMCC No. 62945. The probiotic complex of the present invention can significantly reduce serum uric acid (UA), creatinine (Cr), and blood urea nitrogen (BUN) levels and increase urine excretion of creatinine (Cr) and blood urea nitrogen (BUN) through the synergistic effect of Lactobacillus reuteri FPH2951 and Bifidobacterium breve FPHC4024, and has broad application prospects.

The invention discloses a creatinine detection device, and belongs to the field of in-vitro diagnosis equipment. The creatinine detection device comprises a substrate, a reagent 1 assembly and a reagent 2 assembly, the reagent 1 assembly comprises a flow pad, an enzyme pad and a blood filter membrane, the reagent 2 assembly comprises a start inhibition layer, a separation layer and a color development layer, the reagent 1 assembly and the reagent 2 assembly are stored in a non-contact mode in a normal state, and the reagent 1 assembly and the reagent 2 assembly are in contact to start a reaction during testing; the separation layer contains perfluorooctane sulfonic acid and / or perfluorooctane carboxylic acid. According to the creatinine detection device provided by the invention, interference of endogenous ammonia can be eliminated, the diffusivity of the ammonia is improved, and the detection sensitivity is improved.

The invention discloses combined probiotics for improving sarcopenia as well as a preparation method and application of the combined probiotics, and belongs to the field of probiotics. The invention relates to a combined probiotic for improving sarcopenia. The combined probiotic comprises a lactobacillus reuteri body, a lactobacillus johnsonii body, a lactobacillus fermentum body and a bifidobacterium adolescentis body. The combined probiotics disclosed by the invention can be used for remarkably improving the overall symptoms of sarcopenia model mice, including inhibiting weight loss, constipation symptoms and colonic mucosa destruction, prolonging load swimming time, improving muscle endurance, improving skeletal muscle atrophy, improving the expression of I-type slow muscle fiber protein MyHC I and promoting slow muscle fiber repair, and has the effects of preventing and treating sarcopenia. The invention discloses a probiotic intervention method for treating sarcopenia, which comprises the following steps of: preparing probiotics for treating sarcopenia, reducing the content of inflammatory cytokines in muscular tissues, increasing the content of hepatic glycogen, improving systematic metabolism of mice with sarcopenia and damaged serum markers, including lactic acid, lactic dehydrogenase, creatine kinase, creatinine, alanine transaminase ALT and aspartate transaminase AST, providing a new scheme for probiotic intervention for sarcopenia, and being used for preparing related functional products or intervention means.

The application discloses a composition for protecting liver and strengthening kidney and reducing uric acid, which is made of the following raw material components: Anoectochilus roxburghii, dried tangerine or orange peel, chicory, gardenia, turmeric, Hovenia dulcis Thunb, Cistanche deserticola Y.C.Ma, Rehmannia glutinosa, potassium citrate, sodium citrate and goose myo-peptide. The composition combines the immortal concept of TCM (Traditional Chinese Medicine) "treating disease from the root" and the uric acid control method of modern nutritional medicine as an organic whole, and achieves multiple effects of protecting liver and strengthening kidney, mutual benefit of yin and yang and reducing uric acid through multiple action targets. Animal experiment results show that the composition can effectively reduce the activities of transaminase ALT and AST, relieve liver damage, reduce serum creatinine level and improve urea ammonia excretion rate, improve kidney function, inhibit the activities of xanthine oxidase and adenosine dehydrogenase and reduce uric acid level. The composition is safe and has no toxic side effects, is suitable for people with insufficient liver and kidney functions and hyperuricemia and has a wide application prospect.

The invention relates to the technical field of medicines, in particular to application of lycium barbarum-derived extracellular vesicles in preparation of a medicine for treating acute kidney injury. The used extracellular vesicles derived from Chinese wolfberry fruits have a lipid bilayer membrane structure, are good in stability, free of remarkable toxicity, good in blood compatibility and high in-vivo safety after long-term intravenous injection, are used for preparing the medicine for treating the acute kidney injury, and can reduce apoptosis, inhibit rising of blood urea nitrogen and creatinine levels and relieve injury of kidney tissues; the invention further provides application of the extracellular vesicles derived from the Chinese wolfberry fruits in preparation of the medicine for treating the lung injury disease, the weight loss is relieved, lung tissue is protected, meanwhile, the pulmonary alveolar-capillary barrier can be repaired, and in addition, the medicine can be used for treating the lung injury disease. The invention also provides application of the extracellular vesicles derived from Chinese wolfberry fruits in preparation of nuclear transcription factor kappa B inhibitors and / or inhibition of apoptosis and / or repair of pulmonary alveolar capillary barriers.

The invention relates to the technical field of critical index monitoring methods, in particular to an intelligent critical index monitoring method and system based on clinical data. According to the method, a standardized data packet is constructed by collecting vital sign data of a patient, an inspection index group, drug intervention parameters and individual characteristics of the patient; calculating an individualized drug metabolism correction coefficient based on the liver and kidney function state and a real-time creatinine value, and dynamically generating a drug influence factor in combination with the flow rate of an analgesia pump; scene classification is carried out according to the medicine influence factor value and the blood pressure change trend, and the alarm weight of each monitoring index is dynamically adjusted; and finally, accurate risk assessment and graded early warning are realized through multi-index fusion analysis. The system comprises a data acquisition function module, a dynamic analysis function module, a weight adjustment function module and an early warning decision function module. The clinical problem that a traditional monitoring system is insufficient in sensitivity to progressive deterioration in a drug interference environment is effectively solved, and a more reliable safety monitoring scheme is provided for postoperative high-risk patients.

The invention belongs to the technical field of molecular biology, and particularly relates to a construction method and application of a streptococcus pneumoniae pneumonia animal model. The invention provides a construction method of a streptococcus pneumoniae infected rat pneumonia and kidney injury model. The method comprises the following steps: S1, applying a streptococcus pneumoniae liquid into the respiratory tract of a rat by adopting an atomization bacterium feeding mode; and S2, verifying whether the rat treated in the step S1 is infected with pneumonia or not and whether kidney injury exists or not. According to the method, whether pneumonia is infected or not is judged by detecting inflammatory factors in alveolar lavage and lung HE staining, and whether kidney injury exists or not is judged by detecting the urine protein / creatinine ratio in a rat urine sample and detecting kidney HE staining. The construction method provided by the invention is convenient to operate, accurate in model construction and high in survival rate.

The invention relates to the technical field of medical systems, and particularly discloses a method for constructing a cancer malignant fluid prognosis composite index CCAR based on a creatinine and CAR combination, and the method comprises the following steps: S1, obtaining serum biomarker data of a cancer malignant fluid patient, including creatinine, C-reactive protein and albumin; s2, calculating the ratio CAR of the C reactive protein to the albumin, wherein CAR = CRP / Albumin; s3, taking the CAR and the Cr as input features, and constructing a nonlinear composite index CCAR through a random forest machine learning model; s4, developing a network calculator system; the CCAR index constructed by the invention can comprehensively reflect the inflammation burden, the metabolic state and the immune level of the cancer and malignant fluid patients, and compared with the traditional index, the CCAR index can provide more accurate survival prognosis prediction; creatinine, the ratio of C-reactive protein to albumin and other parameters contained in the CCAR index are all clinical common blood examination items, the obtaining approach is simple and convenient, and wide clinical application is facilitated.

The invention discloses a novel application of Wickerhamomyces anomalus YFJ252 (the preservation number is CGMCC (China General Microbiological Culture Collection Center) NO.28267) which is disclosed and preserved, in particular relates to an application of the strain and a metabolite of the strain in preparation of medicines, foods or health care products for preventing or treating hyperuricemia (HUA), and belongs to the technical field of microorganisms. The strain has excellent probiotic characteristics (acid and cholate resistance, high hydrophobicity, self-aggregation and co-aggregation capability, oxidation resistance, glycometabolism regulation, anti-inflammatory capability and the like) and a function of inhibiting the activity of xanthine oxidase (XO) in vitro. The serum uric acid, creatinine and urea nitrogen levels of a hyperuricemia mouse model induced by high fructose diet and oteracil potassium can be remarkably controlled, and a new way is provided for safely and effectively preventing HUA.

The invention relates to the technical field of clinical decision support and medical data intelligent analysis, in particular to a critical patient individualized liquid resuscitation decision support system, which is characterized in that a data acquisition unit acquires pulse pressure variation waveform and multi-dimensional physiological data of each stroke volume; a volume benefit analysis channel of the dynamic decision-making unit segments a respiratory cycle, extracts pulse pressure fluctuation characteristics, outputs a per-stroke volume increase probability value through a machine learning classifier, an organ injury early warning channel calculates a blood lactic acid and creatinine clearance rate change rate, and generates an acute kidney injury risk sign in combination with inferior vena cava image verification; the execution control unit sends an infusion control or limit instruction according to the combined state; and the feedback optimization unit adjusts the weight of the model according to the actual value of blood lactic acid removal, and recalculates the probability value, so that individualized precise resuscitation, balance capacity benefit and organ protection are realized, and the treatment safety and effectiveness are improved.

The invention provides a traditional Chinese medicine composition for treating nephropathy as well as a preparation method and application thereof, and the anti-renal fibrosis effect is remarkably improved by optimizing a leech extraction process and a novel preparation technology. Animal experiments show that urine protein of model animals can be reduced by 67% and serum creatinine can be reduced by 42% after 12 weeks of continuous administration. Clinical tests prove that the traditional Chinese medicine composition has a definite curative effect on IgA nephropathy, membranous nephropathy and the like, and a new choice is provided for treating chronic kidney diseases.

The disclosure is directed to methods related to creatinine, for example, a method for its safe administration to a human.

The invention belongs to the technical field of biological detection, and particularly relates to a biomarker composition and application thereof in methylation detection of an MGMT promoter. The biomarker composition is prepared from phospholipid (L5PL), creatinine (Creatinine) and ornithine (Ornithine) in the LDL-5 sub-component, and the biomarker composition is prepared from the phospholipid (L5PL), the creatinine (Creatinine) and the ornithine (Ornithine). Whether a glioblastoma patient carries MGMT promoter methylation or not is judged through a plurality of biomarkers, the method has the advantages of being good in sensitivity and specificity, small in patient trauma, capable of overcoming individual differences and the like, and a new solution is provided for prognosis evaluation of glioblastoma.

The invention relates to an application of Avasimibe in preparation of a medicine for treating nasopharynx cancer or oral cancer, and belongs to the field of tumor targeted therapy. An in-vitro cell experiment and an in-vivo animal model experiment verify the anti-tumor effect of the compound. Experiments show that Avasimibe can significantly inhibit the activity, proliferation ability, healing ability and cloning ability of nasopharynx cancer cells and oral cancer cells, can regulate cell cycle arrest in a dose-dependent manner, and induces cell apoptosis. In vivo experiments, the tumor volume of nude mice in an Avasimibe treatment group is remarkably reduced, serum cholesterol is remarkably reduced, and serum biochemical analysis shows that compared with a control group, the Avasimibe treatment group has no statistical difference in indexes such as aspartate transaminase (AST) / glutamic-pyruvic transaminase (ALT) and creatinine (Cr). The invention provides a new indication for resisting nasopharynx cancer and oral cancer for the existing compound Avassimibe, has the clinical advantages of low toxicity and capability of overcoming drug resistance, and provides a new treatment choice for patients with nasopharynx cancer and oral cancer.